Impact of amyloid and cardiometabolic risk factors on prognostic capacity of plasma neurofilament light chain for neurodegeneration

  • for the Alzheimer's Disease Neuroimaging Initiative
  • , Keun You Kim
  • , Eosu Kim
  • , Jun Young Lee
  • , Balebail Ashok Raj
  • , Kristin Fargher
  • , Amanda Smith
  • , Lisa Raudin
  • , Gloria Chaing
  • , Norman Relkin
  • , Karen Elizabeth Smith
  • , Hyungsub Shim
  • , Laura L.Boles Ponto
  • , Susan K. Schultz
  • , Antero Sarrael
  • , Raymundo Hernando
  • , Nunzio Pomara
  • , Dick Drost
  • , Andrew Kertesz
  • , John Rogers
  • Irina Rachinsky, Stephen Pasternak, Elizabether Finger, David Bachman, Kenneth Spicer, Jacobo Mintzer, Bruce L. Miller, Howard J. Rosen, Stephen Correia, Paul Malloy, Stephen Salloway, Geoffrey Tremont, Henry Querfurth, Brian R. Ott, Franklin Watkins, Pradeep Garg, Jeff D. Williamson, Kaycee M. Sink, Eben S. Schwartz, Tamar J. Kitzmiller, Robert B. Santulli, Karen Anderson, Karen Blank, Godfrey D. Pearlson, Alice D. Brown, Dzintra Celmins, Earl A. Zimmerman, Anahita Adeli, Maria Kataki, Douglas W. Scharre, Michelle Rainka, Horacio Capote, Vernice Bates, Stephanie Reeder, Adam Fleisher, Pierre Tariot, Dana Nguyen, Adrian Preda, Steven G. Potkin, Cynthia M. Carlsson, Sanjay Asthana, Sterling Johnson, Rob Bartha, T. Y. Lee, Michael Borrie, Smita Kittur, Charles DeCarli, John Olichney, Owen Carmichael, Evan Fletcher, Leon Hudson, Paula Ogrocki, Alan Lerner, Joanne Allard, Saba Wolday, Thomas O. Obisesan, Patricia Lynn Johnson, Alexander Norbash, Andrew E. Budson, Ronald Killiany, Neil Kowall, Sherye A. Sirrel, Sandra A. Jacobson, Christine M. Belden, Marwan N. Sabbagh, Jared Tinklenberg, Allyson Rosen, Barton Lane, Joy L. Taylor, Jerome Yesavage, Meghan Frey, Gad Marshall, Keith A. Johnson, Reisa A. Sperling, Brigid Reynolds, Kathleen Johnson, Raymond Scott Turner, Teresa Villena, Walter Martinez, Carl Sadowsky, Nancy Johnson, Chuang Kuo Wu, Kristine Lipowski, Marek Marsel Mesulam, Diana Kerwin, Donna Munic, Charles Bernick, Dick Trost, John Rogers, Andrew Kertesz, Michele Assaly, Benita Mudge, Howard Feldman, Ging Yuek Robin Hsiung, Curtis Caldwell, Bojana Stefanovic, Sandra Black, Chris Hosein, Howard Bergman, Howard Chertkow, Martha G. MacAvoy, Richard E. Carson, Christopher H. van Dyck, Cynthia Hunt, Scott Herring, Brandy R. Matthews, Ann Marie Hake, Martin R. Farlow, Heather Johnson, Tracy Kendall, Francine Parfitt, Neill R. Graff Radford, George Bartzokis, Po H. Lu, Daniel H.S. Silverman, Ellen Woo, Kathleen Tingus, Liana Apostolova, Russell H. Swerdlow, Heather S. Anderson, Jeffrey M. Burns, Janet S. Cellar, James J. Lah, Allan I. Levey, Michael DeVous, Kristen Martin Cook, Myron Weiner, Richard King, Ramon Diaz Arrastia, Mary Quiceno, Dana Mathews, Kyle Womack, Catherine Mc Adams Ortiz, Gaby Thai, Ruth A. Mulnard, Connie Brand, M. Saleem Ismail, Kelly M. Makino, Kim Martin, Bonnie S. Goldstein, Anton P. Porsteinsson, Donna M. Simpson, Mary Ann Oakley, Oscar L. Lopez, Gary Conrad, Elizabeth Oates, Partha Sinha, Peter Hardy, Greg Jicha, Charles D. Smith, David Wolk, Jason H. Karlawish, Steven E. Arnold, Terence Z. Wong, Jeffrey R. Petrella, P. Murali Doraiswamy, Susan De Santi, Lidia Glodzik, Mony J. de Leon, Henry Rusinek, Christina A. Michel, Brittany Cerbone, Dana M. Pogorelec, James E. Galvin, Stephanie Kielb, Daniel D’Agostino, Chiadi Onyike, Marilyn Albert, Peggy Roberts, Maria T. Greig, Daniel Varon, Ranjan Duara, Raj C. Shah, Leyla de Toledo-Morrell, Effie Mitsis, Hillel Grossman, Erik Roberson, John Brockington, David Geldmacher, Beau Ances

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Plasma neurofilament light chain (NfL) is a blood biomarker of neurodegeneration, including Alzheimer’s disease. However, its usefulness may be influenced by common conditions in older adults, including amyloid-β (Aβ) deposition and cardiometabolic risk factors like hypertension, diabetes mellitus (DM), impaired kidney function, and obesity. This longitudinal observational study using the Alzheimer’s Disease Neuroimaging Initiative cohort investigated how these conditions influence the prognostic capacity of plasma NfL. Methods: Non-demented participants (cognitively unimpaired or mild cognitive impairment) underwent repeated assessments including the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) scores, hippocampal volumes, and white matter hyperintensity (WMH) volumes at 6- or 12-month intervals. Linear mixed-effect models were employed to examine the interaction between plasma NfL and various variables of interest, such as Aβ (evaluated using Florbetapir positron emission tomography), hypertension, DM, impaired kidney function, or obesity. Results: Over a mean follow-up period of 62.5 months, participants with a mean age of 72.1 years (n = 720, 48.8% female) at baseline were observed. Higher plasma NfL levels at baseline were associated with steeper increases in ADAS-Cog scores and WMH volumes, and steeper decreases in hippocampal volumes over time (all p-values < 0.001). Notably, Aβ at baseline significantly enhanced the association between plasma NfL and longitudinal changes in ADAS-Cog scores (p-value 0.005) and hippocampal volumes (p-value 0.004). Regarding ADAS-Cog score and WMH volume, the impact of Aβ was more prominent in cognitively unimpaired than in mild cognitive impairment. Hypertension significantly heightened the association between plasma NfL and longitudinal changes in ADAS-Cog scores, hippocampal volumes, and WMH volumes (all p-values < 0.001). DM influenced the association between plasma NfL and changes in ADAS-Cog scores (p-value < 0.001) without affecting hippocampal and WMH volumes. Impaired kidney function did not significantly alter the association between plasma NfL and longitudinal changes in any outcome variables. Obesity heightened the association between plasma NfL and changes in hippocampal volumes only (p-value 0.026). Conclusion: This study suggests that the prognostic capacity of plasma NfL may be amplified in individuals with Aβ or hypertension. This finding emphasizes the importance of considering these factors in the NfL-based prognostic model for neurodegeneration in non-demented older adults.

Original languageEnglish
Article number202
JournalAlzheimer's Research and Therapy
Volume16
Issue number1
DOIs
StatePublished - Dec 2024

Keywords

  • Alzheimer’s disease
  • Blood-based biomarker
  • Cardiovascular disease
  • Dementia
  • Kidney disease
  • Metabolic syndrome
  • Neurofilament light chain
  • Prognosis

Fingerprint

Dive into the research topics of 'Impact of amyloid and cardiometabolic risk factors on prognostic capacity of plasma neurofilament light chain for neurodegeneration'. Together they form a unique fingerprint.

Cite this